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During one-year follow-up, 123 (15.2%) patients in the COR group and 40 (14.2%) in
the MVR group experienced at least one MACE (p=0.502). There were no differences
between the two groups in terms of rate of death, myocardial infarction, or
revascularization (2.1 vs. 2.0%, 0.7 vs. 0.8%, and 11.7 vs. 10.1%, respectively;
p=0.908, 0.908, and 0.540, respectively). The MACE rate was higher in the
incompletely revascularized patients than in the completely revascularized patients
(16.2 vs. 9.7%, p=0.017), and the difference was attributable to a higher rate of
nontarget vessel revascularization (8.6 vs. 1.8%, p=002).
Conclusion: Although multivessel angioplasty during primary PCI for STEMI did not
reduce the MACE rate compared with culprit-vessel-only PCI, complete
revascularization was associated with a lower rate of revascularization after multivessel
PCI.
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Background: Multi-vessel disease occurs in 40-65% of patients undergoing Primary
PCI for STEMI and is associated with adverse prognosis. There is limited data
comparing outcomes of complete with infarct-related artery (IRA)-only
revascularisation in primary PCI for STEMI. We therefore sought to clarify the
outcome for those patients dependent on management strategy.
Methods: Prospective data of 2131 STEMI patients was analysed, who underwent
primary PCI between January 2004 and May 2010. Information was entered at the time
of procedure and outcome assessed by all-cause mortality information. Patients were
split into three different treatment groups: culprit vessel angioplasty-only (COR group);
staged revascularisation (SR group) and simultaneous treatment of non-IRA (CR
group). The primary end point used was MACE, defined as death, MI, stroke and TVR.
Results: There were 963 (45%) consecutive patients with STEMI and multivessel
CAD. There were similar baseline characteristics between the 3 groups, aside from
cardiogenic shock, which was significantly higher in the CR group. At 30 days of
follow up, 23/263 (9%) patients in the CR group experienced at least one major adverse
cardiac event (MACE), 1 (1%) in the SR group and 35 (5%) in the CR group (p=0.01).
This trend continued up to 1 year of follow up with the lowest rates of events in the
SR group. However after 3 years MACE rates are significantly increased in the COR
group (24%) but were similar in the CR (18%) and SR (17%) groups. MACE rates
were driven mainly by death in the CR with high rates of TVR in the COR and SR
groups.
Conclusion: Culprit vessel-only angioplasty was associated with the highest rate of
long-term MACE compared with multivessel treatment. Patients scheduled for staged
revascularisation experienced a similar rate of MACE to patients undergoing complete
simultaneous treatment of non-IRA.
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Background: Platelet reactivity (PR) assessment in the very early phase (2 hours post
600mg clopidogrel loading dose-LD) of ST-elevation myocardial infarction (STEMI)
has not been previously reported nor any possible ways to overcome high on-treatment
PR (HTPR).
Methods: In STEMI patients undergoing primary PCI, PR was assessed with the
VerifyNow (Accumetrics Inc., San Diego, CA, USA) assay 2 hours after a 600mg
clopidogrel LD. Patients with HTPR (≥ 235 PR Units), were randomized to either
immediate reloading with 60mg prasugrel/10mg maintenance dose (MD) (group-A)
or clopidogrel 150mg MD starting from the next day (group-B). PR was re-assessed
at 2, 24 hours and at 5 days following randomization. Genotyping was performed for
CYP2C19*2 carriage.
Results: Out of 59 STEMI patients, 38(64.4%) demonstrated HTPR 2 hours post LD
and were all randomized (19 group-A and 19 group-B). PR 2 hours, 24 hours and 5
days post randomization was lower in group-A compared to group-B (Figure 1). HTPR
rate was lower for group-A compared to group-B at 24 hours post randomization in all
patients, in non-carriers and in carriers of 1 CYP2C19*2 loss-of-function allele (5.3%
vs 63.2%, p<0.001, 0% vs 57.1%, p=0.006 and 14.3% vs 100%, p=0.03 respectively).
Conclusion: In STEMI patients, HTPR 2 hours following 600 mg of clopidogrel LD
is very common. An additional reloading with 60 mg of prasugrel followed by a 10
mg MD, achieves greater platelet inhibition compared to clopidogrel 150 mg MD as
early as in 2 hours, a difference that is maintained up to 5 days.
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Background: To study the safety and efficacy of cytoprotector Mexicor (methyl-ethyl-
pyridinol succinate; EcoPharmInvest, Russia) used intracoronary in IRA followed by
angioplasty (stenting) within the first hours after the onset of STEMI.
Methods: The study comprised 191 STEMI patients (mean age 56±7) after successful
primary PCI of totally occluded (TIMI 0) IRA. Before PCI all patients were
randomized into two groups. Patients from Gr.1 (n=96) received 0,2 g of Mexicor in
100 ml of saline solution through microcatheter immediately after recanalization of
IRA before angioplasty. Gr.2 (n=95) comprised patients after successful PCI but
without intracoronary Mexicor use. Main baseline clinical, history and coronary
angiographic data were similar in all cases. Blood sampling for Troponine I was
performed prior to, and in 12 and 24 hours after the procedure. At day 10 as well as in
6 months all patients underwent repeat coronary angiography and left ventriculography.
Results: No complications related to intracoronary use of Mexicor were seen. Survival
during early follow-up was 98,06% in Gr.1 and 98,05% in Gr. 2. Total value of
Troponine I by 24th hour was 292,6±41,5 and 603,7±34,4 ng/ml, respectively (p<0,05).
At day 10 LV EF was 49,7±8,2 and 49,3±9,1, respectively In the mid-term (6,8±0,7
months) survival was 96,8% in Gr.1 and 92,7% in Gr. 2, LV EF was 53,1±9,4% and
48,7±8,3% (p<0,05).
Conclusion: The study suggests that the use of cytoprotector Mexicor intracoronary
in IRA immediately before angioplasty, in our opinion, is safe and limits reperfusion
B19JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/ORAL/STEMI
www.JACC.TCTAbstracts2011
O
R
A
L
S
